17 / 34
Data cutoff: February 26, 2016
a
ITT population;
b
Investigator assessment
CI, confidence interval; HR, hazard ratio; ITT, intention to treat; LET, letrozole;
NR, not reached; PAL, palbociclib; PBO, placebo; PFS, progression-free survival
Finn RS, et al. Poster presented at ASCO 2017
(Abstract 1039)
Time (months)
0
4
8
12
16
20
24
28
32
36
PFS (%)
0
20
40
60
80
100
PAL + LET
PBO + LET
No. at risk
230
208
191
160
147
95
46
7
3
0
112
92
79
65
56
32
13
3
2
0
PBO + LET
Censored
PAL + LET
PAL + LET
(n=230)
PBO + LET
(n=112)
Median (95% CI) PFS, months
NR (25.1–NR)
16.8 (13.7–22.2)
HR (95% CI)
0.50 (0.36–0.70)
P value
<0.0001
Enfermedad Luminal
NO Agresiva
PFS in Patients with Non-visceral Disease